top of page

5 Key Takeaways

IsoMedica's Commercial
opportunity

Growing demand for alpha isotopes, an integrated supply chain and established commercial relationships position IsoMedica to pursue a significant opportunity in the medical isotope market.

WATCH THE FULL interview

Watch the extended video to learn how IsoMedica is helping secure the future of medical isotope supply and radiopharmaceutical innovation.

entX_IsoMedica-Webinar-Cover2.png

OTher Projects

Medical Isotopes

212-Pb

Supply chain process for the manufacture of Lead-212 radiopharmaceuticals

Space & Defence

RHU

Generating heat for critical electronics and lithium batteries to survive the extreme low temperatures of the lunar night.

Space & Defence

GEN X

Maintenance-Free, long term Power for unmanned, remote and challenging Space and Defence applications.

As part of the entX Technology Insights Series, Dr Massey de los Reyes explores five key factors underpinning IsoMedica’s commercial opportunity and entX’s position in the growing alpha isotope market.

1. A Growing Market and Supply Gap

Demand for alpha isotopes is increasing, while reliable supply remains constrained. This creates an opportunity for new production capability and a potential first-mover advantage for businesses able to establish a dependable position in the market.

2. A Differentiated, Vertically Integrated Platform

IsoMedica brings together feedstock access, proprietary purification technology and dedicated production infrastructure. Controlling more of the value chain gives entX a differentiated approach and supports its commercial advantage.

3. Processes Designed for Scale and Reliability

IsoMedica’s production processes are being developed with scalability and repeatability in mind. For commercial customers, consistent and reliable supply is critical, making operational execution just as important as the underlying science.

4. Sovereign Capability as a Strategic Advantage

Australia-based production capability offers more than a local supply option. In a constrained market, sovereign infrastructure can provide strategic and regulatory advantages while strengthening the security and reliability of isotope supply.

5. Established Commercial Relationships

With market demand, an integrated production platform and commercial relationships in place, entX is focused on executing the next stage of IsoMedica’s development in 2026.
Through IsoMedica, entX is working to establish a differentiated Australian medical isotope platform and contribute to more reliable global alpha isotope supply.

Moving from Development to Execution

With market demand, an integrated production platform and commercial relationships in place, entX is focused on executing the next stage of IsoMedica’s development in 2026.

​

Through IsoMedica, entX is working to establish a differentiated Australian medical isotope platform and contribute to more reliable global alpha isotope supply.

bottom of page